Global NON RECEPTOR TYROSINE PROTEIN KINASE TYK2 Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global NON RECEPTOR TYROSINE PROTEIN KINASE TYK2 Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global NON RECEPTOR TYROSINE PROTEIN KINASE TYK2 market finds that the global NON RECEPTOR TYROSINE PROTEIN KINASE TYK2 market reached a value of USD 132.47 million in 2022. It’s expected that the market will achieve USD 3064.58 million by 2028, exhibiting a CAGR of 68.8% during the forecast period.

Non Receptor Tyrosine Protein Kinase TYK2 Growth Drivers

Almost every country in the world is experiencing an increase in the number and proportion of the elderly in its population. According to the data of world population prospects: 2019 revision, by 2050, one sixth of the people in the world will be over 65 years old (16%), which is higher than one tenth (9%) in 2019. By 2050, a quarter of the population living in Europe and North America will be aged 65 or above. In 2018, the number of people aged 65 and over in the world exceeded that of children under 5 for the first time. The number of people aged 80 or above is expected to triple, from 143 million in 2019 to 426 million in 2050. The aging of the population will become an important driving force to promote the growth of the demand in the pharmaceutical market. Therefore, the increasing demand of aging population will promote the development of Non Receptor Tyrosine Protein Kinase TYK2 industry.
Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by TYK2 gene in human body. The gene encodes a member of tyrosine kinase and Janus kinase (JAKs) protein family. This protein binds to the cytoplasmic domains of type I and type II cytokine receptors and promulgate cytokine signals through phosphorylated receptor subunits. It is also a component of type I and type III interferon signaling pathways. Therefore, it may play a role in antiviral immunity. Cytokines play a key role in immunity and inflammation by regulating the survival, proliferation, differentiation and function of immune cells and cells from other organ systems.
Psoriasis is a widespread chronic systemic immune-mediated disease, which seriously damages patients' health, quality of life and work efficiency. Psoriasis is a serious global problem. At least 100 million people around the world are affected by some form of disease, including about 14 million people in Europe and about 7.5 million people in the United States. Nearly a quarter of cases of psoriasis patients are considered to be moderate to severe. Up to 90% of patients with psoriasis suffer from psoriasis vulgaris or plaque psoriasis, which is characterized by obvious round or oval plaques, usually covered with silvery white scales. Despite effective systemic treatment, many patients with moderate to severe psoriasis are still not fully treated or even treated, and they are not satisfied with the current treatment methods.
Non Receptor Tyrosine Protein Kinase TYK2 shows great potential in inflammatory diseases, such as lupus nephritis, psoriatic arthritis, systemic lupus erythematosus and ulcerative colitis.

Region Overview:

From 2023-2028, Asia Pacific is estimated to witness robust growth prospects.

Company Overview:

The top three companies are Bristol-Myers Squibb Company, Pfizer Inc, Nimbus Therapeutics LLC ,with the revenue market share of 38.10%, 9.68% and 11.92% in 2027.

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.

Segmentation Overview:

Among different product types, BMS-986165 segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Psoriasis segment occupied the biggest share from 2018 to 2022.

Key Companies in the global NON RECEPTOR TYROSINE PROTEIN KINASE TYK2 market covered in Chapter 3:

Sareum Holdings Plc
Bristol-Myers Squibb Company
Portola Pharmaceuticals Inc
Pfizer Inc
Nimbus Therapeutics LLC
Takeda Pharmaceutical Company Ltd
Theravance Biopharma Inc

In Chapter 4 and Chapter 14.2, on the basis of types, the NON RECEPTOR TYROSINE PROTEIN KINASE TYK2 market from 2018 to 2029 is primarily split into:

ARRY-624
BMS-986165
Cerdulatinib
NDI-031232
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the NON RECEPTOR TYROSINE PROTEIN KINASE TYK2 market from 2018 to 2029 covers:

Follicular Lymphoma
Hypersensitivity
Lupus Nephritis
Marginal Zone B-cell Lymphoma
Psoriasis
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)